Latest News for: idiopathic pulmonary fibrosis

Edit

GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline (Form 8-K) (Gri Bio Inc)

Public Technologies 14 May 2026
) GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline.
Edit

Idiopathic Pulmonary Fibrosis Clinical Trial Pipeline Accelerates as 80+ Pharma Companies Rigorously Develop Drugs for ...

GetNews 29 Apr 2026
Inactive Products Idiopathic Pulmonary Fibrosis Key Companies Idiopathic Pulmonary Fibrosis Key Products Idiopathic Pulmonary Fibrosis- Unmet Needs Idiopathic Pulmonary Fibrosis- Market Drivers and ...
Edit

Idiopathic Pulmonary Fibrosis Pipeline Progresses as 80+ Pharma Companies Advance Novel Lung Disease Therapies, Finds ...

GetNews 23 Apr 2026
DelveInsight's "Idiopathic pulmonary fibrosis – Pipeline Insight, 2026" report provides comprehensive insights about 80+ companies developing several pipeline drugs in the Idiopathic Pulmonary Fibrosis pipeline landscape.
Edit

Calluna Pharma Completes Enrollment in Phase 2 AURORA Study of CAL101 for Idiopathic Pulmonary Fibrosis (IPF)

The Joplin Globe 22 Apr 2026
OSLO, Norway & BOSTON--(BUSINESS WIRE)--Apr 22, 2026-- ... .
Edit

Vicore Pharma Completes Enrollment in the Phase 2b ASPIRE Trial of Buloxibutid in Idiopathic Pulmonary Fibrosis

The Daily Record - Dunn 22 Apr 2026
The randomized Phase 2b ASPIRE trial successfully completed planned enrollment of over 360 patients, reflecting strong ....
Edit

Calluna Pharma Completes Enrollment in Phase 2 AURORA Study of CAL101 for Idiopathic Pulmonary Fibrosis (IPF) (Forbion Capital Partners Management Services BV)

Public Technologies 22 Apr 2026
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease where an inappropriately activated wound-healing response causes the lung tissue to become thickened and scarred, making it difficult to breathe.
Edit

Idiopathic Pulmonary Fibrosis Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | GSK, Amgen, ...

GetNews 16 Apr 2026
Idiopathic Pulmonary Fibrosis current marketed and Idiopathic Pulmonary Fibrosis emerging therapies ... Idiopathic Pulmonary Fibrosis market drivers and Idiopathic Pulmonary Fibrosis market barriers.
Edit

Cipla Expands U.S. Respiratory Portfolio with Approval of Nintedanib Capsules (100mg & 150mg) for Idiopathic Pulmonary Fibrosis

PR Newswire 03 Apr 2026
The company is set to launch on an immediate basis ... Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Nintedanib Capsules, 100 mg and 150 mg, indicated for the treatment of Idiopathic Pulmonary Fibrosis (IPF) ... .
Edit

United Therapeutics Corporation Announces TETON-1 Pivotal Study of Tyvaso® Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-2 (Form 8-K) (United Therapeutics Corporation)

Public Technologies 30 Mar 2026
United Therapeutics Corporation Announces TETON-1 Pivotal Study of Tyvaso® Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-2.
Edit

Idiopathic Pulmonary Fibrosis Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by ...

GetNews 25 Mar 2026
Idiopathic Pulmonary Fibrosis Molecule Type Idiopathic Pulmonary Fibrosis Products have been categorized under various Molecule types, such as ... Idiopathic Pulmonary Fibrosis current marketed and Idiopathic Pulmonary Fibrosis emerging therapies.
Edit

Idiopathic Pulmonary Fibrosis Clinical Trial Pipeline Expands as 80+ Companies Driving Innovation in the Therapeutics ...

GetNews 20 Mar 2026
Inactive Products Idiopathic Pulmonary Fibrosis Key Companies Idiopathic Pulmonary Fibrosis Key Products Idiopathic Pulmonary Fibrosis- Unmet Needs Idiopathic Pulmonary Fibrosis- Market Drivers and ...
Edit

Baseimmune Announces Strategic Expansion into Fibrosis with Lead Program Targeting Idiopathic Pulmonary Fibrosis (IPF)

Rutland Herald 12 Mar 2026
LONDON--(BUSINESS WIRE)--Mar 12, 2026-- ....
Edit

Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis

The Eagle-Tribune 03 Mar 2026
... and fibrosis indications, announced that it has dosed .
Edit

Idiopathic Pulmonary Fibrosis Market Poised to Reach US$ 6,736.49 Million by 2035 as Late-Stage Pipelines ...

Nasdaq Globe Newswire 09 Feb 2026
Idiopathic pulmonary fibrosis represents a high need specialty market, with global IPF drug sales of ...
Edit

Idiopathic Pulmonary Fibrosis Clinical Trials & Pipeline Overview: Insights into 80+ Leading Companies and 100+ ...

Nasdaq Globe Newswire 09 Feb 2026
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease marked by irreversible fibrosis and poor prognosis ... Idiopathic pulmonary fibrosis (IPF) ...

Article Search

tools
×
×
×
×